NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $57.23 +0.53 (+0.93%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$57.24 +0.02 (+0.03%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BMRN alerts:Sign Up Key Stats Today's Range$56.35▼$57.3950-Day Range$54.38▼$66.5352-Week Range$49.26▼$70.98Volume1.47 million shsAverage Volume2.53 million shsMarket Capitalization$11.09 billionP/E RatioN/ADividend YieldN/APrice Target$87.22Consensus RatingModerate Buy Company Overview BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe. The company’s operations combine a focus on rare-disease research with the development and global commercialization of specialized therapies.AI Generated. May Contain Errors. Read More BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreBMRN MarketRank™: 4.21854478592 of 5 starsBioMarin Pharmaceutical scored higher than 84% of companies evaluated by MarketBeat, and ranked 58th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 strong buy ratings, 15 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialBioMarin Pharmaceutical has a consensus price target of $87.22, representing about 52.4% upside from its current price of $57.23.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth133.64% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 133.64% in the coming year, from $2.20 to $5.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is -572.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is -572.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.76. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.34% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.77.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 17.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.35 News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search InterestOnly 14 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows5 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders0.68% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMRN Stock News HeadlinesBioMarin Pharmaceutical (BMRN) Receives a Buy from Evercore ISINovember 14 at 11:05 PM | theglobeandmail.comBioMarin’s Noonan Syndrome Growth Study Update Raises Investor QuestionsNovember 13 at 11:30 AM | tipranks.comUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.November 15 at 1:00 AM | Paradigm Press (Ad)BioMarin Updates Vosoritide Study in Rare Growth DisorderNovember 12 at 11:51 AM | tipranks.comBioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 11, 2026 | seekingalpha.comBioMarin Pharmaceutical (NASDAQ:BMRN) Raised to Buy at Wall Street ZenNovember 8, 2026 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Target Cut by JPMorgan Chase & Co.November 6, 2026 | americanbankingnews.comBioMarin Pharmaceutical Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 5, 2026 | seekingalpha.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $59.43 at the start of the year. Since then, BMRN stock has decreased by 3.7% and is now trading at $57.23. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Monday, November, 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.28. The company's revenue was up 32.0% on a year-over-year basis. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? Top institutional investors of BioMarin Pharmaceutical include First Trust Advisors LP (0.99%), Assenagon Asset Management S.A. (0.69%), ARGA Investment Management LP (0.38%) and Edmond DE Rothschild Holding S.A. (0.37%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Charles Greg Guyer, Brian Mueller, George Eric Davis, Gregory R Friberg, Cristin Hubbard and Erin Burkhart. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Salesforce (CRM), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN). Company Calendar Last Earnings11/02/2026Today11/15/2026UBS Global Biopharma Conference 202611/16/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BMRN's financial health is in the Yellow zone, according to TradeSmith. BMRN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.biomarin.com Phone(415) 506-6700Fax415-382-7889Employees3,221Year Founded1997Price Target and Rating Average Price Target for BioMarin Pharmaceutical$87.22 High Price Target$114.00 Low Price Target$60.00 Potential Upside/Downside+52.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E Ratio11.13 P/E Growth0.76Net Income$348.90 million Net Margins-0.52% Pretax Margin1.19% Return on Equity5.58% Return on Assets3.51% Debt Debt-to-Equity Ratio0.56 Current Ratio2.44 Quick Ratio1.32 Sales & Book Value Annual Sales$3.66 billion Price / Sales3.03 Cash Flow$2.88 per share Price / Cash Flow19.87 Book Value$32.30 per share Price / Book1.77Miscellaneous Outstanding Shares193,695,000Free Float192,378,000Market Cap$11.09 billion OptionableOptionable Beta0.21 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BMRN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.